Aytu BioPharma (AYTU) Competitors $2.30 -0.04 (-1.71%) As of 01:28 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock AYTU vs. ABOS, EXOZ, IMUX, ASRT, PYXS, KALA, ARTV, IGMS, KLRS, and OSTXShould you be buying Aytu BioPharma stock or one of its competitors? The main competitors of Aytu BioPharma include Acumen Pharmaceuticals (ABOS), eXoZymes (EXOZ), Immunic (IMUX), Assertio (ASRT), Pyxis Oncology (PYXS), KALA BIO (KALA), Artiva Biotherapeutics (ARTV), IGM Biosciences (IGMS), Kalaris Therapeutics (KLRS), and OS Therapies (OSTX). These companies are all part of the "pharmaceutical products" industry. Aytu BioPharma vs. Its Competitors Acumen Pharmaceuticals eXoZymes Immunic Assertio Pyxis Oncology KALA BIO Artiva Biotherapeutics IGM Biosciences Kalaris Therapeutics OS Therapies Acumen Pharmaceuticals (NASDAQ:ABOS) and Aytu BioPharma (NASDAQ:AYTU) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, profitability, earnings, risk, analyst recommendations and media sentiment. Does the media favor ABOS or AYTU? In the previous week, Acumen Pharmaceuticals and Acumen Pharmaceuticals both had 1 articles in the media. Aytu BioPharma's average media sentiment score of 0.50 beat Acumen Pharmaceuticals' score of -0.13 indicating that Aytu BioPharma is being referred to more favorably in the news media. Company Overall Sentiment Acumen Pharmaceuticals Neutral Aytu BioPharma Positive Do insiders & institutionals believe in ABOS or AYTU? 71.0% of Acumen Pharmaceuticals shares are held by institutional investors. Comparatively, 33.5% of Aytu BioPharma shares are held by institutional investors. 7.1% of Acumen Pharmaceuticals shares are held by company insiders. Comparatively, 3.6% of Aytu BioPharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Is ABOS or AYTU more profitable? Aytu BioPharma has a net margin of 2.37% compared to Acumen Pharmaceuticals' net margin of 0.00%. Aytu BioPharma's return on equity of 3.51% beat Acumen Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Acumen PharmaceuticalsN/A -81.39% -61.96% Aytu BioPharma 2.37%3.51%0.91% Which has stronger valuation & earnings, ABOS or AYTU? Aytu BioPharma has higher revenue and earnings than Acumen Pharmaceuticals. Aytu BioPharma is trading at a lower price-to-earnings ratio than Acumen Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAcumen PharmaceuticalsN/AN/A-$102.33M-$2.28-0.59Aytu BioPharma$81M0.25-$15.84M-$0.72-3.19 Do analysts recommend ABOS or AYTU? Acumen Pharmaceuticals currently has a consensus price target of $7.00, indicating a potential upside of 416.61%. Aytu BioPharma has a consensus price target of $10.00, indicating a potential upside of 334.78%. Given Acumen Pharmaceuticals' higher probable upside, analysts plainly believe Acumen Pharmaceuticals is more favorable than Aytu BioPharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Acumen Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00Aytu BioPharma 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more risk and volatility, ABOS or AYTU? Acumen Pharmaceuticals has a beta of 0.14, suggesting that its stock price is 86% less volatile than the S&P 500. Comparatively, Aytu BioPharma has a beta of 0.22, suggesting that its stock price is 78% less volatile than the S&P 500. SummaryAytu BioPharma beats Acumen Pharmaceuticals on 8 of the 13 factors compared between the two stocks. Get Aytu BioPharma News Delivered to You Automatically Sign up to receive the latest news and ratings for AYTU and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AYTU and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AYTU vs. The Competition Export to ExcelMetricAytu BioPharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$20.56M$3.09B$5.75B$9.85BDividend YieldN/A2.28%6.66%4.49%P/E Ratio-3.1820.8882.7926.52Price / Sales0.25369.93499.49162.43Price / CashN/A43.5325.7028.92Price / Book0.508.0310.786.50Net Income-$15.84M-$53.35M$3.28B$266.34M7 Day Performance-0.43%-1.05%-0.42%-1.25%1 Month Performance-13.21%5.84%6.47%3.30%1 Year Performance-3.77%10.76%49.47%23.59% Aytu BioPharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AYTUAytu BioPharma3.9002 of 5 stars$2.30-1.7%$10.00+334.8%-6.0%$20.56M$81M-3.18160News CoverageShort Interest ↓ABOSAcumen Pharmaceuticals2.8449 of 5 stars$1.36+3.8%$7.00+414.7%-43.3%$82.38MN/A-0.6020EXOZeXoZymesN/A$9.70flatN/AN/A$81.36M$70K0.0029Positive NewsIMUXImmunic2.7575 of 5 stars$0.82-5.7%$7.50+814.6%-42.5%$80.89MN/A-0.8770Analyst RevisionASRTAssertio2.0963 of 5 stars$0.84+3.0%$2.38+184.4%-27.0%$80.37M$124.96M-1.8620High Trading VolumePYXSPyxis Oncology1.3699 of 5 stars$1.28-3.8%$8.67+577.1%-57.3%$79.38M$16.15M-0.8060Analyst ForecastGap UpKALAKALA BIO2.8372 of 5 stars$11.22+5.9%$13.00+15.9%+148.1%$78.78M$3.89M-1.6530News CoverageAnalyst UpgradeHigh Trading VolumeARTVArtiva Biotherapeutics3.2422 of 5 stars$3.15-0.3%$17.00+439.7%-71.1%$76.94M$250K0.0081Positive NewsGap UpIGMSIGM Biosciences4.2358 of 5 stars$1.27flat$5.50+333.1%N/A$76.57M$145.05M-1.41190KLRSKalaris Therapeutics0.9743 of 5 stars$4.08+14.6%$3.00-26.5%N/A$76.31MN/A0.00110Analyst ForecastGap DownOSTXOS Therapies2.1271 of 5 stars$2.39+5.8%$18.00+653.1%-47.0%$75.63MN/A-3.03N/ANews CoverageAnalyst Forecast Related Companies and Tools Related Companies Acumen Pharmaceuticals Alternatives eXoZymes Alternatives Immunic Alternatives Assertio Alternatives Pyxis Oncology Alternatives KALA BIO Alternatives Artiva Biotherapeutics Alternatives IGM Biosciences Alternatives Kalaris Therapeutics Alternatives OS Therapies Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AYTU) was last updated on 9/4/2025 by MarketBeat.com Staff From Our PartnersThis Massive Market is Ripe for Disruption by this NasdaqFanatics Hit $31B. This Nasdaq Company Is Building the Next Wave Fanatics built a merch empire by owning th...i2i Marketing Group, LLC | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored2013 Bitcoin miner reveals his trading system (free)While everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | Sponsored“Shadow Group” in Washington, DC Could Crash MarketNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | SponsoredTrump’s betrayal exposedTrump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredDid you spot this in the Oval Office last week?When Tim Cook stood in the Oval Office last week, all eyes were on the "unique 24K gold gift" he presented to ...InvestorPlace | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aytu BioPharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aytu BioPharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
